文献速递炎症性肠病胰腺与胆道疾病

HLA-DQA1-HLA-DRB1多态性是炎症性肠病患者硫唑嘌呤诱导胰腺炎的主要预测因素

HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-12-22

本研究为加拿大伦敦一家三级学术中心的回顾性队列研究,纳入373例接受硫唑嘌呤治疗的炎症性肠病患者,评估rs2647087单核苷酸多态性与硫唑嘌呤诱导胰腺炎风险的关系。结果显示风险高度可预测且基因型依赖:野生型0.53%,杂合型4.25%(OR=4.19),纯合变异型14.63%(OR=15.83)。作者提出基于rs2647087和TPMT基因型的硫唑嘌呤选择与剂量算法。

要点

  • rs2647087野生型(A/A)胰腺炎风险0.53%,杂合型(A/C)4.25%,纯合变异型(C/C)14.63%。
  • 杂合型OR=4.19(95%CI 1.02-36.45,P=0.044),纯合变异型OR=15.83(95%CI 3.80-145.26,P=0.0001)。
  • 作者提出基于rs2647087和TPMT基因型的硫唑嘌呤选择与剂量算法。

核心结论

  • II类HLA区域(rs2647087)是硫唑嘌呤诱导胰腺炎风险的重要标志物,风险高度可预测且基因型依赖。
  • 作者提出基于rs2647087和TPMT基因型的简单且临床可实施的算法,用于炎症性肠病患者硫唑嘌呤的选择和剂量。

研究设计与样本

  • 回顾性队列研究,评估加拿大伦敦一家三级学术中心的373例接受硫唑嘌呤治疗的炎症性肠病患者。
  • 因使用巯嘌呤的患者数量有限,此类患者未纳入本队列。
  • 所有受试者均筛查映射至HLA-DQA1*02:01-HLA-DRB1*07:01单倍型的单核苷酸多态性rs2647087,并根据有无硫唑嘌呤诱导胰腺炎诊断分为有(n=13)和无(n=360)两组。
  • 根据rs2647087基因型评估硫唑嘌呤诱导胰腺炎风险。

主要发现

  • 硫唑嘌呤治疗期间胰腺炎风险高度可预测且基因型依赖:野生型(A/A)0.53%,杂合型(A/C)4.25%(OR=4.19,95%CI 1.02-36.45,P=0.044),纯合变异型(C/C)14.63%(OR=15.83,95%CI 3.80-145.26,P=0.0001)。

临床怎么用

  • 作者提出基于rs2647087和TPMT基因型的简单且临床可实施的算法,用于炎症性肠病患者硫唑嘌呤的选择和剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Azathioprine (AZA)-induced pancreatitis is an unpredictable and dose-independent adverse event affecting 2%-7% of patients with inflammatory bowel disease (IBD) patients treated with AZA. There are no tools in clinical practice to identify at-risk individuals; however, a genome wide association study (GWAS) identified a strong association between the Class II HLA gene region polymorphism (rs2647087) and thiopurine-induced pancreatitis. AIM: To independently confirm the findings of the GWAS in an IBD cohort, to evaluate its utility in clinical practice and to offer a novel AZA treatment algorithm for IBD based on pharmacogenomic principles. METHODS: A retrospective cohort study evaluated 373 AZA-exposed IBD patients from a tertiary care academic centre in London, Canada. Due to the limited number of patients taking mercaptopurine (MP), such patients were not included this cohort. All subjects underwent screening for the single nucleotide polymorphism (SNP) rs2647087 mapped to the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype and were sub-divided based on the presence (n = 13) or absence (n = 360) of an AZA-induced pancreatitis diagnosis. The risk of AZA-induced pancreatitis was assessed based on rs2647087 genotype. RESULTS: The risk of pancreatitis during AZA-therapy was highly predictable and genotype dependent: 0.53% for wild type (A/A), 4.25% (OR = 4.19, 95% CI 1.02-36.45, P = 0.044) for heterozygous (A/C), and 14.63% (OR = 15.83, 95% CI 3.80-145.26, P = 0.0001) for homozygous variant (C/C) patients. CONCLUSIONS: The class II HLA region (at rs2647087) is an important marker of AZA-induced pancreatitis risk. We propose a simple and clinically implementable algorithm based on rs2647087 and TPMT genotypes for AZA selection and dosing for patients with IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wilson A, Jansen LE, Rose RV, et al. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017. PMID: 29270995. doi:10.1111/apt.14483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。